Immunoproteasome Inhibition Ameliorates Aged Dystrophic Mouse Muscle Environment

Muscle wasting is a major pathological feature observed in Duchenne muscular dystrophy (DMD) and is the result of the concerted effects of inflammation, oxidative stress and cell senescence. The inducible form of proteasome, or immunoproteasome (IP), is involved in all the above mentioned processes, regulating antigen presentation, cytokine production and immune cell response. IP inhibition has been previously shown to dampen the altered molecular, histological and functional features of 3-month-old mdx mice, the animal model for DMD. In this study, we described the role of ONX-0914, a selective inhibitor of the PSMB8 subunit of immunoproteasome, in ameliorating the pathological traits that could promote muscle wasting progression in older, 9-month-old mdx mice. ONX-0914 reduces the number of macrophages and effector memory T cells in muscle and spleen, while increasing the number of regulatory T cells. It modulates inflammatory markers both in skeletal and cardiac muscle, possibly counteracting heart remodeling and hypertrophy. Moreover, it buffers oxidative stress by improving mitochondrial efficiency. These changes ultimately lead to a marked decrease of fibrosis and, potentially, to more controlled myofiber degeneration/regeneration cycles. Therefore, ONX-0914 is a promising molecule that may slow down muscle mass loss, with relatively low side effects, in dystrophic patients with moderate to advanced disease.

Automated summary

This study demonstrates that ONX-0914, a selective inhibitor of the PSMB8 subunit of immunoproteasome, improves pathological traits associated with muscle wasting in a mouse model of Duchenne muscular dystrophy. It reduces inflammation, increases regulatory T cells, and buffers oxidative stress, ultimately leading to a decrease in fibrosis. This suggests that ONX-0914 could be a promising therapeutic approach for slowing down muscle mass loss in dystrophic patients.